TVTX · Travere Therapeutics, Inc.

Travere Therapeutics executed a significant refinancing transaction by completing a $525 million public offering of low-coupon 0.50% Convertible Senior Notes maturing in 2032, extending its debt maturity profile from 2029 while locking in minimal interest expense at 0.50% payable semi-annually. The offering was upsized from the initial $475 million firm commitment through full exercise of the $50 million overallotment option, demonstrating strong underwriter and investor demand via J.P. Morgan, Jefferies, and Leerink Partners. Key strategic move involves deploying approximately two-thirds of estimated $508.5 million net proceeds to retire $221.4 million principal of higher-coupon 2.25% 2029 notes at a cash cost of $350.9 million (including accrued interest), reducing near-term debt maturities and interest burden. The notes feature investor-friendly conversion mechanics with an initial rate of 15.4078 shares per $1,000 (≈$64.90 conversion price), potentially dilutive up to 11.7 million shares under maximum conversion scenarios, subject to anti-dilution adjustments. Redemption flexibility begins May 2029 only if stock trades above 130% of conversion price, with make-whole provisions on called notes. Fundamental change repurchase rights provide downside protection. Remaining proceeds bolster liquidity for core biopharma operations including rare disease commercialization and pipeline advancement, positioning Travere for extended runway amid clinical and market development needs.